Mayo Clinic | Strategic Alliance Partners

September 06, 2017

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

August 17, 2017

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).

August 16, 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the desire to use biological heterogeneity as a factor for treatment in newly diagnosed patients with mantle cell lymphoma (MCL).

August 15, 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses difficult challenges to overcome in the landscape of mantle cell lymphoma (MCL).

August 03, 2017

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the possibility of blending immunotherapy agents with chimeric antigen receptor (CAR) T-cell therapy across lymphoma populations.

August 01, 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses what potential immunotherapy agents have in the treatment landscape of mantle cell lymphoma (MCL).

August 01, 2017

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).

July 18, 2017

Tanios Bekaii-Saab, MD, discusses the promise of napabucasin in pancreatic cancer.

July 17, 2017

Two combination regimens anchored by different proteasome inhibitors are being compared in a national clinical trial for patients with newly diagnosed symptomatic multiple myeloma that also seeks to evaluate the ideal duration of lenalidomide (Revlimid) maintenance therapy.

July 05, 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.

June 29, 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses advances in the field of multiple myeloma.

June 22, 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.

June 20, 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the stemness inhibitor napabucasin (BBI-608) as a potential treatment for patients with colorectal cancer (CRC).

May 23, 2017

Sameer Parikh, MD, hematologist, Mayo Clinic, discusses the utilization and significance of the Chronic Lymphocytic Leukemia (CLL)-International Prognostic Index (IPI).

May 18, 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab in multiple myeloma.

May 17, 2017

Sameer A. Parikh, MD, discusses how the International Prognostic Index has assisted physicians with their patients who have CLL, the optimal sequencing of therapies, and other emerging molecular targets in this disease.

May 17, 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses promising combinations in the pipeline for mantle cell lymphoma (MCL).

May 16, 2017

Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

May 16, 2017

Grzegorz S. Nowakowski, MD, an assistant professor of Medicine at Mayo Clinic, discusses the status of emerging agents moving through the pipeline of mantle cell lymphoma.

May 16, 2017

Prashant Kapoor, MD, discusses the importance of minimal residual disease negativity, using International Myeloma Working Group criteria, and field-changing pivotal data in multiple myeloma.